8 research outputs found
Letter from IQVIA to Allergan Finance, LLC (re: National Prescription Opiate Litigation , MDL No. 804, Case No. 17-md-2804 filed in the Northern District of Ohio ; Data: IQVIA data concerning opioids from 1997 to the present, from the following products Allergan has purchased - XPONENT and XPONENT PLANTRAK)
Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Table S1: Baseline Characteristics.Table S2: Treatment Effects â First Line.Table S3: Adverse Events.Table S4: Treatment effects for second/third line treatments (treatment policy estimand).Table S5: Proportion of patients on preventive medication.Table S6: Screening and patient management proportions.Table S7: Sensitivity and specificity of tests.Table S8 Annual treatment costs applied (DKK, AIP 2020, [20]).Table S9 Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).Table S10: Utilities used in CDM.Table S11: Scenario analysis results.Table S12: Breakdown of costs (DKK, per average patient)
Supplementary Tables: Supplementary Materials. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Table S1: Baseline Characteristics.Table S2: Treatment Effects â First Line.Table S3: Adverse Events.Table S4: Treatment effects for second/third line treatments (treatment policy estimand).Table S5: Proportion of patients on preventive medication.Table S6: Screening and patient management proportions.Table S7: Sensitivity and specificity of tests.Table S8 Annual treatment costs applied (DKK, AIP 2020, [20]).Table S9 Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).Table S10: Utilities used in CDM.Table S11: Scenario analysis results.Table S12: Breakdown of costs (DKK, per average patient)
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
Article full text The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see âread the peer-reviewed publicationâ opposite). © The authors, CC-BY-NC 2021